Genmab A (GMAB) Common Equity (2019 - 2026)
Genmab A (GMAB) posted Common Equity of $5.7 billion for Q1 2026, down 2.82% on a QoQ basis from $5.8 billion in Q4 2025, and up 56720.0% year-over-year from N/an in Q1 2025.
Genmab A (GMAB) Common Equity (2019 - 2026) Analysis & Trends
Genmab A's Common Equity history runs 5 years deep, the most recent figure standing at $5.7 billion for Q1 2026.
- Quarterly Common Equity rose 56720.0% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 56720.0% YoY) and the FY2025 annual result came in at $5.8 billion, up 13.82% from the prior year.
- Common Equity was $5.7 billion for Q1 2026 at Genmab A, down from $5.8 billion in the prior quarter.
- Across five years, Common Equity topped out at $5.8 billion in Q4 2025 and bottomed at $10.0 million in Q1 2024.
- A 3-year average of $3.5 billion and a median of $5.2 billion in 2024 frame the typical range for Common Equity.
- Peak annual rise in Common Equity reached 57410.0% in 2025, while the deepest fall reached 0.0% in 2025.
- Genmab A's Common Equity stood at $5.1 billion in 2024, then grew by 13.82% to $5.8 billion in 2025, then slipped by 2.82% to $5.7 billion in 2026.
- Business Quant data shows GMAB's Common Equity at $5.7 billion in Q1 2026, $5.8 billion in Q4 2025, and $5.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 5.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Bn |
| Dec 31, 2025 | 5.85 Bn |
| Sep 30, 2025 | 5.75 Bn |
| Jun 30, 2025 | 5.30 Bn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 5.14 Bn |
| Sep 30, 2024 | 10.00 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Sep 30, 2020 | 18,477.00 |
| Dec 31, 2019 | 14,048.00 |
| Sep 30, 2019 | 12.51 Bn |